A proven track record of value creation
We are a multinational pharmaceutical company with a local presence across North America and Canada, MENA and Europe, providing our customers with a broad range of generic, specialty and branded pharmaceutical products
Full year 2025 results
Khalid Nabilsi, Deputy CEO, North America and Europe
Our purpose is to put better health within reach, every day
Sustainability reporting
We are dedicated to ensuring patients across the US, Canada, Europe, and the MENA region have access to high-quality medicines. Our mission is to advance health and wellbeing by empowering our people, protecting the environment, and operating with transparency and ethically.
Annual Report
In 2024 we have continued to deliver on our mission to help shape a healthier world, and our leadership teams are advancing this agenda across our markets. We have been launching new products, signing partnerships, investing more into research and development, building new manufacturing plants, and deploying capital through acquisition to ensure we are well placed for continued growth.
Latest news
Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes
- Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes Press Release, Financial Results 26 February 2026 Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes
- Hikma launches authorised generic of Nucynta® (tapentadol) in the US Press Release, Product 25 February 2026 Hikma launches authorised generic of Nucynta® (tapentadol) in the US
- Notice of results Press Release, Financial Results 03 February 2026 Notice of results
- Hikma announces launch of Enoby™ (denosumab- qbde) and Xtrenbo™ (denosumab- qbde) referencing Prolia® and Xgeva® respectively Press Release, Product 19 January 2026 Hikma announces launch of Enoby™ (denosumab- qbde) and Xtrenbo™ (denosumab- qbde) referencing Prolia® and Xgeva® respectively